Compositions and methods for beta-glucan immunotherapy
US10092646B2 · kind B2 · utility
1Cited by
4References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2013 |
| Grant date | Oct 9, 2018 |
| Priority date | — |
| Expiry date | Dec 11, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2400/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.